Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML

Acute myeloid leukemia (AML) is a high remission, high relapse fatal blood cancer. Although mTORC1 is a master regulator of cell proliferation and survival, its inhibitors have not performed well as AML treatments. To uncover the dynamics of mTORC1 activity in vivo, fluorescent probes are developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, Toshihiko, Mercier, Francois, Kato, Hiroki, Jung, Yookyung, McDonald, Thomas O., Spencer, Joel A., Mazzola, Michael C., van Gastel, Nick, Lin, Charles P., Michor, Franziska, Kitamura, Toshio, Scadden, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801403/
https://www.ncbi.nlm.nih.gov/pubmed/33431855
http://dx.doi.org/10.1038/s41467-020-20491-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801403/
https://www.ncbi.nlm.nih.gov/pubmed/33431855
http://dx.doi.org/10.1038/s41467-020-20491-8

Ejemplares similares